Following the February 2011 acquisition of 02h, Piramal Pharma Solutions has re-branded its discovery chemistry and ADME services as Piramal Discovery Solutions. The re-branding reflects Piramal’s expansion into the contract discovery and development services. The company can now offer integrated drug discovery solutions from discovery chemistry to clinical trials.

O2h’s discovery capabilities include integrated teams of FTE-based medicinal chemistry, synthetic chemistry and in-vitro ADMET. The company is currently expanding its biology capabilities.

“The re-branding to Piramal Discovery Solutions reflects the aim of the group to be a fully integrated service provider to those that discover and develop new small molecule drugs for the treatment of disease,” said Sunil Shah, chief executive officer, Piramal Discovery Solutions. “This is also the next logical step in integration to provide robust technology transfer protocols between the nine Piramal sites around the globe as a molecule moves from early phase to later phases of development.”